Financial Performance - Revenue for Q3 2023 reached ¥279,643,980.09, an increase of 12.59% compared to the same period last year, and a year-to-date revenue of ¥928,444,491.99, up 33.57% year-on-year[5] - Net profit attributable to shareholders for Q3 2023 was ¥53,405,435.34, a significant increase of 126.07% year-on-year, with a year-to-date net profit of ¥127,675,726.10, up 69.68%[5] - Basic earnings per share for Q3 2023 was ¥0.20, representing a 122.22% increase compared to the same period last year[5] - Total operating revenue for Q3 2023 reached CNY 928,444,491.99, an increase of 33.6% compared to CNY 695,091,597.02 in Q3 2022[24] - Net profit for Q3 2023 was CNY 126,754,539.70, representing a 63.6% increase from CNY 77,460,054.36 in Q3 2022[25] - Total comprehensive income for the third quarter reached CNY 126,858,527.06, compared to CNY 77,914,778.97 in the same period last year, representing an increase of approximately 62.5%[26] - Basic and diluted earnings per share increased to CNY 0.47 from CNY 0.28, reflecting a growth of 67.9% year-over-year[26] Assets and Liabilities - Total assets at the end of Q3 2023 amounted to ¥3,377,330,888.09, reflecting a growth of 7.79% from the end of the previous year[5] - The company's total assets increased to CNY 3,377,330,888.09, up from CNY 3,133,329,649.02 at the end of Q3 2022[22] - Total liabilities rose to CNY 1,258,175,401.07, compared to CNY 1,139,602,540.86 in the previous year[22] - The equity attributable to shareholders of the parent company increased to CNY 2,100,134,698.62, up from CNY 1,973,785,133.36 in the previous year[22] Cash Flow - Cash flow from operating activities showed a negative net amount of ¥166,824,156.27 year-to-date, indicating a decline of 119.64%[5] - Cash inflow from operating activities totaled CNY 783,133,547.81, up from CNY 758,665,013.57, indicating a growth of 3.2%[27] - Net cash flow from operating activities was negative CNY 166,824,156.27, worsening from negative CNY 75,952,785.61 in the previous year[27] - Cash outflow for investment activities was CNY 70,229,339.03, significantly reduced from CNY 197,086,130.00, a decrease of 64.4%[27] - Net cash flow from financing activities improved to CNY 149,307,756.21 from CNY 45,282,007.16, an increase of 230.5%[27] - The ending balance of cash and cash equivalents was CNY 114,271,926.04, slightly down from CNY 117,495,909.16 year-over-year[27] - The company reported a significant increase in cash received from sales of goods and services, totaling CNY 667,402,052.00, compared to CNY 652,134,938.08 in the previous year[27] Operational Metrics - Operating costs for Q3 2023 grew by 34.20%, primarily driven by the increase in revenue[12] - Total operating costs for Q3 2023 were CNY 774,166,708.76, up 26.2% from CNY 613,666,273.60 in the same period last year[24] - Research and development expenses for Q3 2023 amounted to CNY 48,147,621.68, an increase from CNY 45,131,474.61 in Q3 2022[25] - Financial expenses rose by 44.36%, mainly due to increased bank loan interest[13] - The company experienced a rise in financial expenses, totaling CNY 12,344,009.13, compared to CNY 8,550,967.19 in Q3 2022[25] Shareholder Information - The top shareholder, Beijing Liweit Investment Co., Ltd., holds 18.75% of the shares, amounting to 51,209,771 shares, with 28,725,170 shares pledged[19] - The second-largest shareholder, Changsha Xinting Zhizhen Medical Investment Partnership, holds 6.92% of the shares, totaling 18,913,639 shares[19] - The company has a total of 9,050 common shareholders as of the end of the reporting period[19] Future Outlook - The company is focusing on expanding its capabilities in the smart manufacturing and rehabilitation medical equipment sectors, which are key drivers for revenue growth[11] - Future outlook and guidance will be provided in subsequent reports, focusing on market expansion and new product development strategies[19] Accounting and Audit - The company has not undergone an audit for the third quarter report[28] - The company is implementing new accounting standards starting in 2023, which may affect financial reporting[28]

证券代码：300430 证券简称：诚益通 公告编号：2023-058 二、董事会会议审议情况 审议通过《关于公司<2023 年第三季度报告>的议案》 具体内容详见同日披露在中国证监会指定创业板信息披露网站巨潮资讯网 （http://www.cninfo.com.cn）上发布的公告。 表决结果：同意票 9 票，反对票 0 票，弃权票 0 票。 三、备查文件 北京诚益通控制工程科技股份有限公司 第五届董事会第三次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 北京诚益通控制工程科技股份有限公司（以下简称"公司"）第五届董事会 第三次会议通知已于 2023 年 10 月 20 日以电子邮件、专人送达等方式发出，并 于 2023 年 10 月 26 日在公司会议室召开。本次会议应出席董事 9 人，实际参会 董事 9 人。会议的召开符合法律、行政法规、部门规章及《公司章程》的规定， 合法有效。 《北京诚益通控制工程科技股份有限公司第五届董事会第三次会议决议》。 特此公告。 北京诚益通控制工程科技股份有限公司 董事会 2023 年 1 ...

证券代码：300430 证券简称：诚益通 公告编号：2023-059 北京诚益通控制工程科技股份有限公司 第五届监事会第三次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、监事会会议召开情况 北京诚益通控制工程科技股份有限公司（以下简称"公司"）第五届监事会 第三次会议通知于 2023 年 10 月 20 日以电子邮件、专人送达等形式发出，并于 2023 年 10 月 26 日在公司会议室以现场形式召开。会议应出席监事 3 人，实际 出席监事 3 人，由监事会主席刘泽君先生主持。会议的召开符合法律、行政法规、 部门规章及《公司章程》的规定，合法有效。 二、监事会会议审议情况 表决结果：同意票 3 票，反对票 0 票，弃权票 0 票。 三、备查文件 《北京诚益通控制工程科技股份有限公司第五届监事会第三次会议决议》。 特此公告。 北京诚益通控制工程科技股份有限公司 监事会 2023 年 10 月 27 日 审议通过《关于公司<2023 年第三季度报告>的议案》 全体监事认为，公司《2023 年第三季度报告》的编制和审议程序符合法律、 行政法规及监 ...

证券代码：300430 证券简称：诚益通 公告编号：2023-056 北京诚益通控制工程科技股份有限公司 关于全资子公司为母公司提供担保的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、融资情况概述 北京诚益通控制工程科技股份有限公司（以下简称"公司"）于 2023 年 4 月 26 日召开了第四届董事会第二十次会议，会议审议通过了《关于公司及子公 司、孙公司申请银行综合授信及项目贷款额度的议案》、《关于为公司及子公司、 孙公司申请综合授信及项目贷款提供担保的议案》（公告编号：2023-017、018）， 同意公司、子公司及合并报表范围内的子公司、孙公司向银行及其他金融机构申 请合计额度不超过人民币 12.30 亿元的授信等业务，在授权期限内额度可循环使 用，担保总额合计不超过上述金额。上述议案同时由 2023 年 5 月 17 日召开的 2022 年度股东大会审议通过。 二、融资进展情况 近期，公司与上海浦东发展银行股份有限公司北京分行（以下简称"浦发银 行"）签署《综合授信合同》，授信额度为6,000万元。公司全资子公司北京诚 益通科技有限公 ...

北京诚益通控制工程科技股份有限公司 关于控股股东部分股权解除质押的公告 证券代码：300430 证券简称：诚益通 公告编号：2023-055 公司控股股东北京立威特投资有限责任公司保证向公司提供的信息内容真 实、准确、完整，没有虚假记载、误导性陈述或重大遗漏，本公司及董事会全 体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或 重大遗漏。 北京诚益通控制工程科技股份有限公司（以下简称"公司"或"本公司"） 近日接到公司控股股东北京立威特投资有限责任公司（以下简称"立威特"）的 通知，获悉其持有的本公司股份办理了部分股权解除质押业务，具体事项如下： 一、股份变动的基本情况 截至公告披露日，上述股东及其一致行动人所持质押股份情况如下： 股东 名称 持股 数量 （万股） 持股 比例 本次解 除质押 前质押 股份数 量 本次解除 质押后质 押股份数 量 占其所持 股份比例 占公司 总股本 比例 已质押股份 情况 未质押股份 情况 已质押股 份限售和 冻结数量 占已质 押股份 比例 未质押股 份限售和 冻结数量 (万股) 占未质 押股份 比例 | 立威特 | 5120.98 | 18.74% | 31 ...

北京诚益通控制工程科技股份有限公司（以下简称"公司"或"本公司"） 近日接到公司控股股东北京立威特投资有限责任公司（以下简称"立威特"）的 通知，获悉其持有的本公司股份办理了部分股权解除质押及质押业务，具体事项 如下： 一、股份变动的基本情况 | 股东 名称 | 是否为控 股股东或 第一大股 | 本次解 除质押 | 占其所 持股份 | 占公司 总股本 | 是否为 限售股 （如是， | 是否为 补充质 | 质押起 始日 | 质押到 期日 | 质权人 | 质押 用途 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | 东及其一 致行动人 | 数量（万 股） | 比例 | 比例 | 注明限 售类型） | 押 | | | | | | 立威特 | 是 | 240 | 4.69% | 0.88% | 否 | 否 | 2022 年 9 月 5 日 | 2023 年 9 月 13 日 | 北京兴展 融达融资 担保有限 公司 | 经营 业务 开展 | | 合计 | - | 240 | 4.69% | 0.88% | - | - | ...

证券代码：300430 证券简称：诚益通 公告编号：2023-052 北京诚益通控制工程科技股份有限公司 关于为子公司提供担保的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、融资情况概述 北京诚益通控制工程科技股份有限公司（以下简称"公司"）于 2023 年 4 月 26 日召开了第四届董事会第二十次会议，会议审议通过了《关于公司及子公 司、孙公司申请银行综合授信及项目贷款额度的议案》、《关于为公司及子公司、 孙公司申请综合授信及项目贷款提供担保的议案》（公告编号：2023-017、018）， 同意公司、子公司及合并报表范围内的子公司、孙公司向银行及其他金融机构申 请合计额度不超过人民币 12.30 亿元的授信等业务，在授权期限内额度可循环使 用，担保总额合计不超过上述金额。上述议案同时由 2023 年 5 月 17 日召开的 2022 年度股东大会审议通过。 二、融资进展情况 注册资本：人民币 10,000 万元 经营范围：技术开发、转让、咨询、服务；销售工业自动化控制系统装置、 机械设备、电子产品、计算机软硬件及外围设备、卫生用品、消毒用品 ...

Financial Performance - The company's operating revenue for the first half of 2023 was ¥648,800,511.90, representing a 45.24% increase compared to ¥446,711,611.07 in the same period last year[23]. - The net profit attributable to shareholders for the first half of 2023 was ¥74,270,290.76, up 43.88% from ¥51,621,096.01 in the previous year[23]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥72,189,143.96, reflecting a 50.20% increase from ¥48,062,950.29 year-on-year[23]. - The basic earnings per share for the first half of 2023 was ¥0.27, a 42.11% increase compared to ¥0.19 in the same period last year[23]. - The total assets at the end of the reporting period were ¥3,308,077,242.39, which is a 5.58% increase from ¥3,133,329,649.02 at the end of the previous year[23]. - The net assets attributable to shareholders at the end of the reporting period were ¥2,045,342,958.33, up 3.63% from ¥1,973,785,133.36 at the end of the previous year[23]. - The net cash flow from operating activities was -¥71,335,220.71, a decline of 98.17% compared to -¥35,997,732.88 in the same period last year[23]. - The weighted average return on net assets was 3.69%, an increase of 0.93% from 2.76% in the previous year[23]. Strategic Focus and Development - The company has established a dual-driven development strategy focusing on smart manufacturing and rehabilitation medical equipment, aiming to become a service provider in the health sector[32]. - The company emphasizes the importance of risk awareness regarding forward-looking statements in the report[4]. - The company is positioned to benefit from favorable policies promoting the development of smart manufacturing in the pharmaceutical industry, particularly during the "14th Five-Year Plan" period[35]. - The company aims to leverage technologies such as the internet, robotics, and artificial intelligence to expand its presence in the health sector, focusing on integrated smart manufacturing solutions[105]. - The company plans to enhance its R&D capabilities and expand its product line to address increasing market competition in the pharmaceutical and rehabilitation medical equipment sectors[133]. Product and Market Expansion - The smart manufacturing business primarily serves pharmaceutical and bioproduct manufacturing companies, providing comprehensive smart manufacturing solutions[33]. - The company focuses on expanding its smart manufacturing business by broadening its service areas to include chemical synthesis, traditional Chinese medicine extraction, and biopharmaceuticals, which are expected to drive new growth[45][46]. - The rehabilitation medical device sector is experiencing rapid growth, with China's rehabilitation demand reaching 460 million people in 2019, driven by an aging population and increasing prevalence of neurological diseases[52]. - The company has developed specialized solutions for six major fields, including pain rehabilitation and neurological rehabilitation, providing targeted "one-stop" solutions for common diseases[62]. - The company is actively expanding its product offerings, with several devices registered in the last few years, indicating a commitment to innovation and market growth[88]. Financial Management and Investments - The company has a robust supplier assessment system to ensure timely procurement of raw materials based on sales forecasts and production plans[72]. - The production model for rehabilitation medical devices is based on inventory production, allowing for timely delivery upon customer orders[74]. - The company has committed a total of 30,876.72 million CNY for investment projects, with 29,519.1 million CNY already invested, achieving an investment progress of 95.6%[122]. - The company has temporarily supplemented working capital with 3.9 million CNY from idle raised funds, with a usage period not exceeding 12 months from the board approval date[124]. - The company reported a significant decrease in investment, with a 100% drop from CNY 106,000,000.00 in the previous year to CNY 0.00 in the current period[118]. Regulatory Compliance and Corporate Governance - The company has established a research and development risk control system to mitigate risks associated with long development cycles, high technical difficulty, and significant funding requirements in the pharmaceutical and rehabilitation medical equipment sectors[134]. - The company has not engaged in any derivative investments during the reporting period, indicating a conservative investment strategy[128]. - The company has not reported any overdue amounts or impairment risks related to its entrusted financial management activities[127]. - The company has not experienced any significant changes in the feasibility of its investment projects during the reporting period[125]. - The company has committed to fulfilling its corporate social responsibilities, ensuring compliance with laws and regulations, and maintaining investor rights[149]. Market Presence and Brand Recognition - The company has established a strong market presence, with its products being used in over 5,000 medical institutions domestically and exported to over 30 countries[59]. - The brand "Chengyitong" has gained significant recognition in the industry, providing a solid foundation for market share expansion[103]. - The company is expanding its market presence in Europe, with plans to enter three new countries by the end of the fiscal year[92]. - The company is actively promoting its brand through academic activities, enhancing its reputation and influence in the rehabilitation sector[69]. Future Outlook - The company provided guidance for the next quarter, projecting revenue growth of 20% to $180 million[93]. - Future strategies include increasing investment in digital marketing to boost user engagement and brand awareness[93]. - The company anticipates growth in the rehabilitation market, driven by an increasing demand for innovative medical devices and therapies[89]. - The company aims to enhance its market presence through the introduction of innovative rehabilitation devices, targeting specific patient needs such as swallowing dysfunction and limb strength deficiency[89].

证券代码：300430 证券简称：诚益通 公告编号：2023-047 北京诚益通控制工程科技股份有限公司 第五届董事会第二次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 会议由公司董事长梁凯先生主持，经参会董事认真审议，形成决议如下： 一、审议通过《关于公司<2023 年半年度报告>及其摘要的议案》 经审议，董事会一致认为：公司《2023 年半年度报告》及其摘要真实反映 了公司 2023 年上半年的财务状况和经营成果，符合法律、行政法规、中国证监 会及深圳证券交易所的相关规定，报告内容真实、准确，完整，不存在任何虚假 记载、误导性陈述或者重大遗漏。同意公司对外报出。 具体内容详见同日披露在中国证监会指定创业板信息披露网站巨潮资讯网 （http://www.cninfo.com.cn）上发布的公司《2023 年半年度报告》全文及摘 要。 表决结果：同意票 9 票，反对票 0 票，弃权票 0 票。 二、审议通过《关于公司<2023 年半年度募集资金存放与使用情况专项报告> 的议案》 经审议，董事会认为该专项报告的编制符合相关法律、法规的规定，真实、 ...

北京诚益通控制工程科技股份有限公司独立董事 关于第五届董事会第二次会议相关事项的独立意见 北京诚益通控制工程科技股份有限公司（以下简称"公司"）第五届董事会 第二次会议于 2023 年 8 月 24 日在公司会议室召开，根据《公司法》、《证券法》、 《关于在上市公司建立独立董事制度的指导意见》、《深圳证券交易所创业板股 票上市规则》、《深圳证券交易所创业板上市公司规范运作指引》等法律法规以 及《北京诚益通控制工程科技股份有限公司章程》的有关规定，我们作为公司的 独立董事，本着实事求是、认真负责的态度，基于独立判断、审慎、客观的立场， 现就本次董事会相关事项发表如下独立意见： 一、关于控股股东及其他关联方占用公司资金的独立意见 2023 年上半年，公司与关联方之间的资金往来属正常的经营性资金往来， 不存在公司的控股股东、实际控制人及其他关联方占用公司资金的情况。也不存 在以前年度发生并累积至 2023 年 6 月 30 日的控股股东及其他关联方违规占用公 司资金的情况。 二、关于公司对外担保情况的独立意见 报告期内，公司除对子公司担保外，不存在其他形式的对外担保事项，也不 存在以前年度发生并累积至 2023 年 ...